Regulation of mesenchymal phenotype by MicroRNAs in cancer.

abstract：:Prostate cancer is the most frequently diagnosed tumor in industrialized countries. Endocrine therapy, which is based on interference with androgen signaling is only palliative. Drugs used in prostate cancer therapy are luteinizing hormone releasing hormone (LHRH) agonists and antiandrogens. Application of LHRH agonis...

journal_title：Current cancer drug targets

authors： Culig Z,Bartsch G,Hobisch A

更新日期：2004-08-01 00:00:00

abstract：:Constitutive activation of the EGFR/RAS/PI3K cell-signaling pathway that may occur through molecular aberrations in core pathway components occurs in many solid tumours, including colorectal cancer(CRC), non-small-cell lung cancer(NSCLC) and breast cancer. Predictive biomarkers of response to therapeutics targeting th...

journal_title：Current cancer drug targets

authors： Barton S,Starling N,Swanton C

更新日期：2010-12-01 00:00:00

abstract：BACKGROUND:Approximately one third of Diffuse Large B cell Lymphomas (DLBCL) are refractory or relapse. Novel therapeutic approaches under scrutiny include inhibitors of B-cell receptor (BCR) signaling. Protein kinase CK2 propels survival, proliferation and stress response in solid and hematologic malignancies and prom...

journal_title：Current cancer drug targets

authors： Mandato E,Nunes SC,Zaffino F,Casellato A,Macaccaro P,Tubi LQ,Visentin A,Trentin L,Semenzato G,Piazza F

更新日期：2018-01-01 00:00:00

abstract：:As microtubules are essential in many cell functions, they have been used as a target of a variety of anticancer drugs that are grouped as stabilizing (taxanes) and destabilizing (vinca-alkaloids, colchicinoids) microtubule agents. It appears clearly now that the dynamic behaviour more than modifications of microtubul...

journal_title：Current cancer drug targets

authors： Beghin A,Galmarini CM,Dumontet C

更新日期：2007-12-01 00:00:00

abstract：:Cetuximab (IMC-C225, Erbitux ImClone Systems Inc, New York, NY) is a recombinant, human/mouse chimeric monoclonal antibody (MAb) that binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of epidermal g...

journal_title：Current cancer drug targets

authors： Vincenzi B,Zoccoli A,Pantano F,Venditti O,Galluzzo S

更新日期：2010-02-01 00:00:00

abstract：:Bisphosphonates are the standard of care for preventing skeletal morbidity and treating hypercalcemia of malignancy in patients with bone metastases. Zoledronic acid (intravenous; 4 mg monthly) is approved to prevent skeletal-related events (SREs) in patients with bone metastases from several tumor types, and can impr...

journal_title：Current cancer drug targets

authors： Gnant M

更新日期：2009-11-01 00:00:00

abstract：:The Jun oncoprotein is a major component of the transcription factor complex AP-1, which regulates the expression of multiple genes essential for cell proliferation, differentiation and apoptosis. Constitutive activation of endogenous AP-1 is required for tumor formation in avian and mammalian cell transformation syst...

journal_title：Current cancer drug targets

authors： Hartl M,Bader AG,Bister K

更新日期：2003-02-01 00:00:00

abstract：:Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal disorders of hematopoietic progenitors manifest by cytopenias, bleeding, infection, and potential for progression to acute myelogenous leukemia. The wide spectrum of clinical manifestations, including variability in illness severity and potential for ...

journal_title：Current cancer drug targets

authors： Warlick ED,Smith BD

更新日期：2007-09-01 00:00:00

abstract：:Several subtypes of T cells are located in a tumor environment, each of which supplies their energy using different metabolic mechanisms. Since the cancer cells require high levels of glucose, the conditions of food poverty in the tumor environment can cause inactivation of immune cells, especially the T-effector cell...

journal_title：Current cancer drug targets

authors： Iranparast S,Tayebi S,Ahmadpour F,Yousefi B

更新日期：2020-01-01 00:00:00

abstract：:Recent publications on the molecular characterization of malignant glioma have had profound impact on the appreciation of tumoral heterogeneity within and between patients. Both these phenomena are implicated in the variability in clinical outcome between patients, as well as the inevitable recurrence of these tumors ...

journal_title：Current cancer drug targets

authors： Balvers RK,Dirven CM,Leenstra S,Lamfers ML

更新日期：2017-01-01 00:00:00

abstract：:The experimental cytotoxic drug cyclopentenyl cytosine (CPEC) is an analogue of cytidine. Besides its antiviral effect, its potential use in the treatment of cancer has become an important area of research. CPEC is activated by intracellular phosphorylation ultimately forming its metabolite CPEC-TP. CPEC-TP is a non c...

journal_title：Current cancer drug targets

authors： Schimmel KJ,Gelderblom H,Guchelaar HJ

更新日期：2007-08-01 00:00:00

abstract：:Preferentially expressed antigen in melanoma (PRAME) is the best characterized member of the PRAME family of leucine-rich repeat (LRR) proteins. Mammalian genomes contain multiple members of the PRAME family whereas in other vertebrate genomes only one PRAME-like LRR protein was identified. PRAME is a cancer/testis an...

journal_title：Current cancer drug targets

authors： Hermes N,Kewitz S,Staege MS

更新日期：2016-01-01 00:00:00

abstract：:Head and neck cancer, the sixth most common type of cancer worldwide, is associated with a dismal prognosis that has minimally improved during the last few decades. Future advances in the treatment and prognosis of this fatal disease largely rely upon a better understanding of the molecular events that underlie tumor ...

journal_title：Current cancer drug targets

authors： Nikitakis NG,Siavash H,Sauk JJ

更新日期：2004-12-01 00:00:00

abstract：:Targeted therapies focus on signaling pathways in cancer cells and other molecular processes involved in oncogenesis. Recent approaches affect the following major groups: the epidermal growth factor receptor (EGFR)-family, angiogenesis, the eicosanoid pathway, the PKC/ Ras/ MAPK pathway, the proteasome and inducers of...

journal_title：Current cancer drug targets

authors： Auberger J,Loeffler-Ragg J,Wurzer W,Hilbe W

更新日期：2006-06-01 00:00:00

abstract：:Arsenic trioxide (As2O3) has been used in the clinic for the treatment of acute promyelocytic 1eukemia and some solid tumors. However, its effectiveness against lung cancer has not been well demonstrated, and the underlying mechanism(s) of action remain unclear. In the present study, we found that As2O3 significantly ...

journal_title：Current cancer drug targets

authors： Yang MH,Zang YS,Huang H,Chen K,Li B,Sun GY,Zhao XW

更新日期：2014-01-01 00:00:00

abstract：:Aberrant expression of the RON receptor tyrosine kinase contributes to breast cancer malignancy. Although clinical trials of RON targeting are underway, the intriguing issue is the diversity of RON expression as evident by cancer cells expressing different variants including oncogenic RON160. The current study determi...

journal_title：Current cancer drug targets

authors： Yao HP,Zhuang CM,Zhou YQ,Zeng JY,Zhang RW,Wang MH

更新日期：2013-07-01 00:00:00

abstract：:Over the past two decades, a number of chemical entities have been investigated in the continuing quest to reverse P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in cancer cells and some have undergone clinical trials, but currently none are in clinical use. Unfortunately, most of these agents suffer clinic...

journal_title：Current cancer drug targets

authors： Mayur YC,Peters GJ,Prasad VV,Lemo C,Sathish NK

更新日期：2009-05-01 00:00:00

abstract：:Following the discovery that defective retinoid signaling directly contributes to tumorigenesis, and, that retinoids have an anti-cancer effect in vitro and in vivo, retinoids have become part of the routine care in children with neuroblastoma at the stage of minimal residual disease. However, many patients still rela...

journal_title：Current cancer drug targets

authors： Cheung BB,Marshall GM

更新日期：2011-09-01 00:00:00

abstract：:Breast cancer is one of the most prevalent and devastating malignant diseases in women worldwide. Fortunately, while breast cancer incidence is still increasing, its death rate is declining. This is mainly due to early diagnosis and potent therapies such as blockade of estrogen receptor- or of ErbB2 (HER2-neu) membran...

journal_title：Current cancer drug targets

authors： Grunt TW,Mariani GL

更新日期：2013-02-01 00:00:00

abstract：:Bid, a BH3-only Bcl-2 family member, is proven to be a pivotal molecule for the regulation of tumorigenesis by its multiple functions in promoting apoptosis, survival and proliferation. Growing evidence supports that Bid has double roles with respect to stress-response. In most cases it functions in a truncated form, ...

journal_title：Current cancer drug targets

authors： Song G,Chen GG,Hu T,Lai PB

更新日期：2010-09-01 00:00:00

abstract：:The application of nanotechnology to biomedical research is expected to have a major impact leading to the development of new types of diagnostic and therapeutic tools. One focus in nanobiotechnology is to develop safe and efficient drug/gene delivery vehicles. Research into the rational delivery and targeting of phar...

journal_title：Current cancer drug targets

authors： Liu Y,Lou C,Yang H,Shi M,Miyoshi H

更新日期：2011-02-01 00:00:00

abstract：BACKGROUND:Osteosarcoma is an aggressive bone tumor. Itrepresents the principal cause of cancer-associated death in children.Considering the recent findings on the role of iron in cancer, iron chelation has been investigated for its antineoplastic properties in many tumors. Deferasirox is the most used iron chelator co...

journal_title：Current cancer drug targets

authors： Argenziano M,Di Paola A,Tortora C,Di Pinto D,Pota E,Di Martino M,Perrotta S,Rossi F,Punzo F

更新日期：2020-12-29 00:00:00

abstract：BACKGROUND:The solute carrier family 7 (SLC7) can be categorically divided into two subfamilies, the L-type amino acid transporters (LATs) including SLC7A5-13, and SLC7A15, and the cationic amino acid transporters (CATs) including SLC7A1-4 and SLC7A14. Members of the CAT family transport predominantly cationic amino ac...

journal_title：Current cancer drug targets

authors： Lu X

更新日期：2019-01-01 00:00:00

abstract：:Androgen deprivation therapy has been the major treatment for advanced prostate cancer (PCa) and has shown to prolong life. However, remissions are temporary and patients almost inevitably progress to become castration-resistant prostate cancer (CRPC). CRPC is almost incurable even when treated with docetaxel that may...

journal_title：Current cancer drug targets

authors： Donkena KV,Yuan H,Young CY

更新日期：2010-06-01 00:00:00

abstract：:Polyisoprenylated proteins (PPs) methylation by polyisoprenylated protein methyl transferase (PPMTase) is counteracted by polyisoprenylated methylated protein methyl esterase (PMPMEase). This is the only reversible step of the polyisoprenylation pathway as the relative amounts of the acid and ester forms are determine...

journal_title：Current cancer drug targets

authors： Duverna R,Ablordeppey SY,Lamango NS

更新日期：2010-09-01 00:00:00

abstract：:Targets for cancer therapy are conventionally selected by identification of molecules acting downstream of established tumour suppressors and oncoproteins, such as p53, c-Myc and Ras. However, the forward genetics approach provides an alternative, conceptually distinct, strategy for identifying target molecules de nov...

journal_title：Current cancer drug targets

authors： Mourtada-Maarabouni M,Watson D,Munir M,Farzaneh F,Williams GT

更新日期：2013-01-01 00:00:00

abstract：:The resistance of tumors to a number of structurally and functionally unrelated chemotherapeutic drugs has been a major obstacle for successful cancer chemotherapy. An important mechanism leading to multidrug resistance (MDR) is the overexpression of the 170 kDa P-glycoprotein (P-gp), which is a member of the ATP-bind...

journal_title：Current cancer drug targets

authors： Santos SA,Paulo A

更新日期：2013-10-01 00:00:00

abstract：:Various signal transduction pathways have been implicated in the pathogenesis of chronic lymphocytic leukemia (CLL), which is characterized by the progressive accumulation of monoclonal CD5+ B cells in the blood. B cell receptor (BCR) signaling appears to have a crucial role in disease onset and is thought to be induc...

journal_title：Current cancer drug targets

authors： Muggen AF,Singh SP,Hendriks RW,Langerak AW

更新日期：2016-01-01 00:00:00

abstract：:Prostate cancer (CaP) is a major health problem in males in Western countries. Current therapeutic approaches are limited and many patients die of secondary disease (metastases). There is no cure for metastatic castration-resistant prostate cancer (CRPC). Targeting tumor-associated antigens is fast emerging as an area...

journal_title：Current cancer drug targets

authors： Hao JL,Cozzi PJ,Khatri A,Power CA,Li Y

更新日期：2010-05-01 00:00:00

abstract：:Angiogenesis is crucial for tumor development and progression, and antiangiogenetic therapy represents a promising approach for cancer treatment. Thus, the in-depth understanding of the molecular mechanism(s) regulating angiogenesis, together with the characterization of molecules expressed by endothelial cells and in...

journal_title：Current cancer drug targets

authors： Fonsatti E,Sigalotti L,Arslan P,Altomonte M,Maio M

更新日期：2003-12-01 00:00:00